Inclusion Criteria:
- Documented histologically or cytologically confirmed, advanced,
unresectable/metastatic solid tumor measurable by RECIST v1.1.
- CRC: Part 1A, Part 2A-CRC, Part 1B, and Part 2B:.
i) Locally advanced/metastatic, recurrent, or unresectable CRC with adenocarcinoma
histology and whose disease has progressed after systemic cancer therapy in the
metastatic or adjuvant setting including 5-FU, irinotecan, and/or oxaliplatin (if
available and not contraindicated).
- NSCLC: Part 2A-NSCLC/GC, 3L+ NSCLC:.
i) Histologically confirmed NSCLC meeting stage criteria for Stage IIIB, Stage IV,
or recurrent disease.
ii) Progressed on at least 2 prior lines of therapy,
iii) Participants must have received and progressed on or after anti-PD-(L)1 therapy, if
available.
- GC: Part 2A-NSCLC/GC, 2L+ GC:.
i) Participants must have received and then progressed or been intolerant to at least 1
standard treatment regimen in the advanced or metastatic setting (or have progressed
within 6 months of adjuvant therapy).
ii) ECOG performance status of 0 or 1.
Exclusion Criteria:
- History of anaphylactic reactions to irinotecan and/or bevacizumab.
- Previously received therapy targeting CEACAM5.
- Grade ≥ 3 ILD/pneumonitis.
- Other protocol-defined Inclusion/Exclusion criteria apply.
